Epigenica Expands Into Japan Through PrimeTech Partnership To Advance Epigenetic Research
20 March 2026 | Friday | News
Distribution agreement brings EpiFinder platform to leading research institutions enabling high throughput biomarker discovery and precision medicine innovation across the Japanese life sciences ecosystem
Image Source : Public Domain
Epigenica AB, a company commercializing advanced tools for epigenetic analysis, announced a distribution agreement with PrimeTech Co., Ltd., a leading distributor of life science technologies in Japan. The partnership will bring Epigenica’s EpiFinder™ technologies to researchers and laboratories across the Japanese market.
Japan represents one of the world’s most advanced life science ecosystems, with strong investment in genomics, biomarker discovery, and translational research. Through this collaboration, PrimeTech will distribute Epigenica’s EpiFinder kits and support local researchers in adopting the technology for epigenetic analysis and biomarker discovery.
"Japan is a highly innovative market with world leading research institutions and strong interest in advanced omics technologies," said Mohamad Takwa, CEO and co-founder of Epigenica. "We are delighted to partner with PrimeTech to make EpiFinder more accessible to researchers in Japan and support new discoveries in areas such as cancer biology, aging research, and precision medicine."
PrimeTech has extensive experience supporting life science researchers and introducing innovative technologies to the Japanese market.
"We are very pleased to collaborate with Epigenica and introduce the EpiFinder technology to researchers in Japan," said Ryosuke Ogihara, CEO of PrimeTech. "The ability to generate epigenetic information at the scale that EpiFinder offers opens exciting opportunities for biomarker discovery and translational research."
Epigenica’s EpiFinder platform enables high throughput epigenetic profiling across different cell types and tissues, as well as the detection of epigenetic signals in blood through circulating nucleosomes. This provides researchers with a powerful tool to study gene regulation and discover novel epigenetic biomarkers.
The agreement represents an important step in Epigenica’s international commercialization strategy and further expands access to its technologies in key research markets.
"Japan is a highly innovative market with world leading research institutions and strong interest in advanced omics technologies," said Mohamad Takwa, CEO and co-founder of Epigenica. "We are delighted to partner with PrimeTech to make EpiFinder more accessible to researchers in Japan and support new discoveries in areas such as cancer biology, aging research, and precision medicine."
PrimeTech has extensive experience supporting life science researchers and introducing innovative technologies to the Japanese market.
"We are very pleased to collaborate with Epigenica and introduce the EpiFinder technology to researchers in Japan," said Ryosuke Ogihara, CEO of PrimeTech. "The ability to generate epigenetic information at the scale that EpiFinder offers opens exciting opportunities for biomarker discovery and translational research."
Epigenica’s EpiFinder platform enables high throughput epigenetic profiling across different cell types and tissues, as well as the detection of epigenetic signals in blood through circulating nucleosomes. This provides researchers with a powerful tool to study gene regulation and discover novel epigenetic biomarkers.
The agreement represents an important step in Epigenica’s international commercialization strategy and further expands access to its technologies in key research markets.
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
